


COVER LEGEND



The United States has made the solution of the cancer problem one of the national goals, expressed by the National Cancer Institute Act of 1937 and the National Cancer Act of 1971. (Texts of these laws are reprinted in: *J. Natl. Cancer Inst.*, 19: 133-137, 1957, and 48: 577-584, 1972, respectively.) The annual budget for cancer is now over 600 million dollars (see *Cancer Res.*, 34: 1743-1748, 1974).

Frank Joseph Rauscher, Jr., in 1972 became director of the National Cancer Institute and the National Cancer Plan. He was born in Hellertown, Pennsylvania, in 1931, was graduated from Moravian College in 1953, and obtained his Ph.D. in microbiology from Rutgers University in 1957. He joined the National Cancer Institute in Bethesda, Maryland, in 1959, continuing research in viral aspects of cancer, which included the identification of a murine leukemia virus known by his name.

The National Cancer Act of 1971 established a three-man President's Cancer Panel as well as an expanded National Cancer Advisory Board. The group photograph was taken at one of the 1972 meetings of both. From *left to right*, seated, are:

1. Sidney Farber, M.D. (deceased 1973), Children's Cancer Research Foundation, Boston, Massachusetts (now the Sidney Farber Institute),
2. Frank J. Dixon, M.D., Scripps Clinic and Research Foundation, La Jolla, California,
3. Sol Spiegelman, Ph.D., Institute of Cancer Research, College of Physicians and Surgeons,

Columbia University, New York, New York,

4. Jonathan E. Rhoads, M.D., School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (Chairman of Board),

5. Frank J. Rauscher, Jr., Ph.D.,

6. Mary Lasker, Albert and Mary Lasker Foundation, New York, N. Y.,

7. Benno C. Schmidt, LL.B., J. H. Whitney and Co., New York, New York (Chairman of Panel),

8. Robert Q. Marston, M.D., Director, National Institutes of Health, Bethesda, Maryland (ex-officio),

9. R. Lee Clark, M.D., M. D. Anderson Hospital and Tumor Institute, Houston, Texas.

From *left to right*, standing, are:

1. D. Murray Angevine, M. D., Armed Forces Institute of Pathology, Washington, D. C. (ex-officio),

2. Joseph H. Ogura, M.D., School of Medicine, Washington University, St. Louis, Missouri,

3. Philippe Shubik, M.D., The Eppley Institute for Research in Cancer, University of Nebraska, Omaha, Nebraska,

4. Kenneth R. Krabbenhoft, M.D., School of Medicine, Wayne State University, Detroit, Michigan,

5. John R. Hogness, M.D., Institute of Medicine, National Academy of Sciences, Washington, D. C.,

6. James D. Watson, M.D., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York,

7. William W. Shingleton, M.D., Duke University Medical Center, Durham, North Carolina,

8. Harold P. Rusch, M.D., University of Wisconsin Medical Center, Madison, Wisconsin,

9. Arnold L. Brown, M.D., Mayo Clinic, Rochester, Minnesota,

10. Harold Amos, Ph.D., Harvard Medical School, Boston, Massachusetts,

11. Gerald P. Murphy, M.D., Roswell Park Memorial Institute, Buffalo, New York,

12. Donald E. Johnson, Advertiser's Press, Flint, Michigan.

Eleven other members of the Board and one other member of the Panel, as well as three ex-officio members, were absent.

The background is the wheel of the National Cancer Program Strategy Hierarchy, developed for the National Cancer Plan.

We are indebted to the National Cancer Institute for the photographs.

M. B. S.